Ugurlu Bera Omer, Malkan Umit Yavuz
Division of Hematology, Department of Internal Medicine, Hacettepe University Medical Faculty, Ankara, Turkey.
SAGE Open Med Case Rep. 2025 Mar 25;13:2050313X251330969. doi: 10.1177/2050313X251330969. eCollection 2025.
Dasatinib is an effective agent in the treatment of bcr-abl positive acute lymphoblastic leukemia and chronic myeloid leukemia cases. Various skin reactions may occur when tyrosine kinase inhibitors are used. The severity of side effects increases in phototoxic reactions with sunlight. In this case, a phototoxic rash that developed in a 78-year-old bcr-abl positive acute lymphoblastic leukemia patient is presented. This case supports that phototoxic reactions may occur with dasatinib and emphasizes that clinicians should be alert for this side effect.
达沙替尼是治疗bcr-abl阳性急性淋巴细胞白血病和慢性粒细胞白血病病例的有效药物。使用酪氨酸激酶抑制剂时可能会出现各种皮肤反应。副作用的严重程度在阳光引起的光毒性反应中会增加。在此，报告了一名78岁bcr-abl阳性急性淋巴细胞白血病患者发生的光毒性皮疹。该病例支持达沙替尼可能会引起光毒性反应，并强调临床医生应警惕这种副作用。
